Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs
Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
EP: 1.Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs
EP: 2.Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs
EP: 3.Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs
EP: 4.Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events
EP: 5.Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs
EP: 6.Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs
EP: 7.Experts Discuss Common AEs With EGFR TKIs
EP: 8.Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC
EP: 9.Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs
EP: 10.Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs
EP: 11.Experts on the Management of Diarrhea Associated With EGFR TKIs
Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
Jeanne G. Vaughn, NP is a nurse practitioner at Massachusetts General Hospital Cancer Center. Kristina Lo, PharmD, BCOP, is a pharmacist, Oncology Specialty Program Services, at University of California (UC) Davis. Jonathan Riess, MD, MS, is the medical director of Thoracic Oncology, an associate professor of Medicine, Division of Hematology & Oncology, UC Davis Comprehensive Cancer Center. Ticiana Leal, MD, is an associate professor and director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Vaughn, Lo, Reiss, and Leal say that dose reductions are common when treating patients with EGFR TKIs; vigilance remains important when utilizing moisturizers to manage skin toxicities that occur when using EGFR TKIs. Moreover, each individual EGFR TKI can lead to different types of skin rashes and bacteria, making it important to involve dermatologists in treatment considerations.
Additionally, Leal explains that a rash flare up can increase the risk of infection. When flare ups occur, dose reduction and pauses should be considered, as well as the multidisciplinary involvement of dermatologists, Leal concludes.
